BioStock: Chordate comments on Q4 and case report

Chordate Medical has published the year-end report for 2023, which showed an increase in sales compared to the previous year. The company has also recently published a case report strengthening the company’s position. The case report describes the experience of a 60-year-old migraine patient who underwent the Ozilia treatment, resulting in reduction in the frequency of migraine days and the level of pain.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/04/chordate-comments-on-q4-and-case-report/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se